ReviewAnais brasileiros de dermatologia
Cutaneous mucormycosis.
Review in Anais brasileiros de dermatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 1 synthesis or guideline pooled it, 158 citations in OpenAlex.
- A retrospective analysis for the management of oromaxillofacial invasive mucormycosis and systematic literature review.BMC oral health · 2023Pooled it
- Cutaneous mucormycosis in a patient with Hailey-Hailey disease (benign familial pemphigus) - first reported case.Medical mycology case reports · 2026Article
- Computed Tomography Findings in Pathology-Confirmed Rhino-Orbital Mucormycosis During the COVID-19 Era: A Retrospective Cross-Sectional Study.Health science reports · 2026Article
- A Rare Case of Cutaneous Mucormycosis byClinical case reports · 2026Article
- Coronavirus disease 2019-associated mucormycosis and cytomegalovirus infection: a case report.Journal of medical case reports · 2026Article
- Post-COVID-19 Rhinocerebral Mucormycosis, a Life-Threatening Event in the Background of an Immunosuppressive Condition: A Case Report.Iranian journal of pathology · 2026Article
- Monoclonal Antibodies Can Aid in the Culture-Based Detection and Differentiation ofAntibodies (Basel, Switzerland) · 2025Article
- Cutaneous mucormycosis: Unveiling rare manifestations.Journal of family medicine and primary care · 2025Article
- Fungal Infections in People Who Use Drugs.Open forum infectious diseases · 2025Review
- Climate Change Impacts on Environmental Fungi: Human Health and Fungal Disease.Current topics in microbiology and immunology · 2025Review
- The Comprehensive Management of Patients with Rhino-Orbito-Cerebral Mucormycosis; A Perspective from Antifungal Treatment to Prosthetic Rehabilitation: A Descriptive Cohort Study.Tropical medicine and infectious disease · 2024Article
- Cutaneous mucormycosis with suspected dissemination in a patient with metastatic adrenocortical carcinoma.Medical mycology case reports · 2024Article
- Mucormycosis during COVID-19 era: A retrospective assessment.Infectious medicine · 2024Review
- Mucormycosis: A Rare disease to Notifiable Disease.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Review
- Oral mucormycosis associated with COVID-19 and diabetes mellitus: Case report and literature reviewBiomedica : revista del Instituto Nacional de Salud · 2024Review
- A rare case of mucormycosis in a diabetic patient: diagnostic challenges and clinical management of mucormycosis hand infection.Case reports in plastic surgery & hand surgery · 2024Article
- Fungal Necrotizing Fasciitis Due to Mucormycosis Following Contaminated Substance Inoculation: A Report of Two Cases.European journal of case reports in internal medicine · 2024Article
- Article
- Advancements of fish-derived peptides for mucormycosis: a novel strategy to treat diabetic compilation.Molecular biology reports · 2023Review
- Insulin and early debridement keys to survival in-COVID 19 associated mucormycosis patients(CAM)- An experience from tertiary care hospital In India.Journal of diabetes and metabolic disorders · 2023Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous mucormycosis is an emerging fungal infection caused by opportunistic fungi of the phylum Glomeromycota. It is frequent in poorly controlled diabetic patients and individuals with immunosuppression. It is usually acquired by direct inoculation through trauma. The clinical presentation is nonspecific, but an indurated plaque that rapidly evolves to necrosis is a common finding. Diagnosis should be confirmed by demonstration of the etiological agent and new molecular diagnostic tools have recently been described. It is an invasive life-threatening disease and in order to improve survival, a prompt diagnosis and multidisciplinary management should be provided. The treatment of choice is amphotericin B, but new azoles, such as posaconazole and isavuconazole, must be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.